Dicerna Pharmaceuticals (DRNA) Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)
4/21/2014 9:45:31 AM
WATERTOWN, Mass.--(BUSINESS WIRE)--Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leader in the development of RNAi-based therapeutics, today announced that it granted stock options to Pankaj Bhargava, M.D., the Company’s chief medical officer, on April 16, 2014, including a stock option to purchase 246,406 shares of common stock of the Company outside of the Company’s stockholder approved equity incentive plan. The grant of this stock option was approved by the compensation committee of the board of directors on April 16, 2014 as an inducement material to Dr. Bhargava entering into employment with the Company in reliance on NASDAQ Listing Rule 5635(c)(4).
Help employers find you! Check out all the jobs and post your resume.
comments powered by